ANORMED REPORTS PROGRESS ON MOZOBIL STUDY

AnorMED has reported that additional clinical trial sites have been added to the company's Mozobil Phase III clinical trials. AnorMED is also recruiting patients into five Phase II trials for Mozobil, including trials in Germany and Canada, and plans to initiate one new Phase II trial by the end of 2005.

Mozobil is a stem cell mobilizer. By blocking CXCR4, a specific cellular receptor, the drug triggers the rapid movement of stem cells out of the bone marrow and into circulating blood. Once in the circulating blood, the stem cells can be collected for use in stem cell transplant. Stem cell transplant is a procedure used to restore the immune system of cancer patients who have had treatments that previously destroyed their immune cells.